What is HLA‑B27, when should it be tested, and how are HLA‑B27‑associated spondyloarthropathies managed?

HLA-B27: Testing Indications and Clinical Management

HLA-B27 testing should be ordered in patients under 45 years old with chronic low back pain (>3 months duration) who have either inflammatory back pain features OR when sacroiliitis imaging is unavailable, as it provides a 90% sensitivity and 32% post-test probability for axial spondyloarthritis. 1

What is HLA-B27?

HLA-B27 is a human leukocyte antigen (class I MHC molecule) strongly associated with spondyloarthropathies. It is present in 74-89% of patients with axial spondyloarthritis (axSpA) 2. The exact pathogenic mechanism remains unclear, but three main hypotheses exist: (1) presentation of arthritogenic peptides triggering autoreactive CD8+ T cells, (2) formation of cell-surface dimers activating innate immune receptors, and (3) misfolding in the endoplasmic reticulum causing inflammatory responses 3, 4.

When to Test for HLA-B27

Primary Care Screening Criteria

Test HLA-B27 when ALL of the following are present:

• Chronic low back pain >3 months duration
• Age of symptom onset <45 years
• EITHER inflammatory back pain features OR need for screening when imaging unavailable 1

Inflammatory Back Pain Features (at least 3-4 of these):

• Morning stiffness >30 minutes
• Pain at night/early morning hours
• Improvement with exercise (not rest)
• Alternating buttock pain
• Symptom onset before age 35-40 years
• First-degree family member with spondyloarthritis
• Current/previous arthritis, enthesitis, or psoriasis 2, 5

Key Testing Characteristics

HLA-B27 is an excellent screening test because:

• Sensitivity: 90% (only 10% of axSpA patients are missed)
• Specificity: 90%
• Likelihood ratio: 9
• Post-test probability: 32% (only 3 HLA-B27+ patients need rheumatology referral to diagnose 1 case)
• One-time test with <5% false positive/negative rate
• No variability over time 1

When NOT to Test

Do not use HLA-B27 for:

• Screening asymptomatic populations 6
• Ruling out disease based solely on negative result 5
• Patients without the clinical context above (age >45, acute pain, mechanical back pain)

Important caveat: Axial spondyloarthritis occurs equally in men and women, can occur in HLA-B27 negative patients (10-26%), and is possible without radiographic sacroiliitis 2, 5. A negative HLA-B27 does not exclude disease.

Referral to Rheumatology

Refer immediately when:

• HLA-B27 positive + chronic low back pain (>3 months) + age <45 years 1
• Inflammatory back pain features present (regardless of HLA-B27 status)
• Sacroiliitis on x-ray or MRI in young patient with chronic back pain 1
• At least 4 of the inflammatory back pain criteria listed above, OR 3 criteria + HLA-B27 positive 5

Do not delay referral for:

• Normal ESR/CRP (only 50% sensitive in early disease) 1
• Negative HLA-B27 if clinical suspicion remains high
• Absence of radiographic sacroiliitis (may take 7+ years to develop) 7

Management of HLA-B27-Associated Spondyloarthropathies

First-Line Treatment (All Patients)

1. NSAIDs at full dose - central role as first-choice pharmacologic treatment 8

   • Trial for 2-4 weeks
   • If ineffective, switch to another NSAID
   • Use lowest effective dose with ongoing monitoring

2. Structured exercise program - refer all patients to subspecialist for this 5, 8

   • Consider adding hydrotherapy for pain management

Escalation to Biologic Therapy

Initiate TNF inhibitor (TNFi) when:

• High disease activity despite adequate trial of ≥2 NSAIDs (or intolerance/contraindication)
• AND at least one of:
  • Elevated C-reactive protein
  • Definite inflammation on MRI
  • Radiographic evidence of sacroiliitis 8

Biologic treatment algorithm:

• First biologic: TNF inhibitor (preferred over secukinumab or ixekizumab) 9
• If primary TNFi failure: Switch to secukinumab or ixekizumab (preferred over second TNFi) 9
• TNFi, secukinumab, ixekizumab all preferred over tofacitinib 9

What NOT to Do

Do not use:

• Methotrexate co-administration with TNFi (not recommended) 9
• Conventional DMARDs for predominant axial involvement 8
• Sulfasalazine except for persistent peripheral arthritis when TNFi contraindicated 9, 8
• Systemic glucocorticoids for axial disease 8
• Strict treat-to-target strategy 9
• Routine tapering/discontinuation of biologics in stable disease 9

Monitoring

• Do NOT routinely monitor with serial spine radiographs 9
• Consider MRI of spine/pelvis only when disease activity is unclear 9
• Monitor clinical response to treatment, functional status, and quality of life

Special Considerations

For peripheral arthritis: Corticosteroid injections for monoarthritis; standard DMARDs for polyarthritis/oligoarthritis 5

For acute anterior uveitis: Immediate ophthalmology referral for eye pain or redness 5

HLA-B27 positivity predicts worse prognosis - another reason early identification and treatment is critical 1

The key to optimal outcomes is early recognition through appropriate HLA-B27 testing in the right clinical context, prompt rheumatology referral, and aggressive treatment with NSAIDs followed by biologics when indicated, while avoiding ineffective therapies like methotrexate or systemic steroids for axial disease.